Skin Elements Nears Commercial Launch with Five SE Formula Products

Five SE Formula Products Primed for Market Entry

Skin Elements Limited (ASX:SKN) has reached a significant milestone with its SE Formula biotechnology platform now commercialisation ready across five natural formulations. These include the Elizabeth Jane Natural Cosmetics, Soléo Organics sunscreen, PapayaActivs therapeutic skincare, SuprCuvr disinfectants, and ECO-Nurture horticultural bio-stimulants. After 20 years and $50 million invested in research, the company is transitioning from development to market rollout, aiming to capitalise on growing demand for safer, plant-based alternatives to chemical products.

The company emphasises the scientific validation behind these products, highlighting their superior efficacy in real-world applications, which underpin their readiness for commercial scale sales. This progress follows a series of successful evaluations and independent laboratory verifications, including the acclaimed Soléo Organics sunscreen, rated number one globally by Environmental Working Group and independently verified by Consumer NZ.

ECO-Nurture and SuprCuvr Evaluations Signal Market Potential

Skin Elements has completed extensive field evaluations of its ECO-Nurture bio-stimulant in New Zealand kiwifruit orchards over three growing seasons, delivering over 6,400 litres of concentrate across 120 orchards. The product demonstrated effective plant protection without chemical residues. The company is now awaiting New Zealand government approval under the Agricultural Compounds Veterinary Medicines Act and is actively seeking commercial partners for the upcoming 2026 kiwifruit season.

Meanwhile, SuprCuvr, a hospital-grade disinfectant cleaner made from 100% plant-based ingredients, has been adopted by Spotless for daily cleaning and disinfecting of Melbourne suburban train carriages and stations. This follows two years of independent testing and distribution through Bunzl's MCS Victoria facilities. Skin Elements plans to develop a commercial strategy to expand SuprCuvr’s distribution in large-scale cleaning services and retail markets. These developments build on the company’s earlier progress securing regulatory listings on the Australian Register of Therapeutic Goods and New Zealand’s Ministry of Primary Industry.

Cashflow Management and Funding Position

Financially, Skin Elements reported net operating cash outflows of $634,000 for the quarter ending 31 March 2026, driven by $975,000 invested in manufacturing, staff, and R&D, partly offset by $51,000 in customer receipts from test marketing. Cash on hand stood at $905,000, supplemented by an undrawn $404,000 R&D rebate advance facility with Radium Capital, providing approximately two quarters of funding runway at current burn rates.

The company continues to manage its resources prudently, balancing investment in product commercialisation with operational costs. The R&D rebate remains a key support, with a $404,000 rebate assessed for FY2026 and $288,000 advanced in early April. This financial discipline follows a $2.5 million capital raise completed earlier in the year to fund the SE Formula rollout, which was part of a broader funding strategy including equity issues and option exercises. The company’s cashflow and funding status reflect ongoing development investment amid a challenging biotech commercialisation cycle.

Boardroom Turbulence Ahead of Shareholder Meeting

Amid operational progress, Skin Elements faces corporate governance challenges with an extraordinary general meeting called to consider resolutions for director removals and appointments. Notices under the Corporations Act have triggered this meeting, with recently appointed directors Joshua Gordon and Roderick Nicholas seeking to install a board majority aligned with their interests. They have publicly criticised the company’s business plan without offering alternatives.

Executive Chairman Peter Malone has urged shareholders to review the company’s notice of meeting carefully and vote in line with the board’s recommendations, which defend the current strategy and highlight past successes and future plans. This boardroom dispute introduces uncertainty over the company’s strategic direction and governance stability at a critical juncture for commercialisation efforts.

Skin Elements’ recent moves, including the planned acquisition of the Mount Ida Gold Project, suggest a diversification strategy that may further complicate investor sentiment and operational focus. The company’s ability to navigate these internal tensions while advancing product launches will be a key watchpoint for investors.

With the SE Formula platform set to enter commercial markets and regulatory approvals pending, Skin Elements stands at a crossroads where execution and governance will test the company’s resilience and growth prospects in the natural antimicrobial biotechnology sector.